3E Bioventures Forms China JV for Peripheral Neuropathy Therapy with Regenacy

3E Bioventures Capital, a Beijing healthcare investor, formed a JV with Regenacy Pharma of Massachusetts to develop a novel drug for peripheral neuropathies. Ricolinostat is a novel, clinical-stage. oral, selective histone deacetylase 6 (HDAC6) inhibitor. By inhibiting HDAC, ricolinostat reestablishes the transport function of microtubules in the axon of the nerve cell to restore nerve function. Initially, the JV will conduct a China trial of ricolinostat to test its safety and efficacy in patients with chemotherapy-induced peripheral neuropathy. More details.... Share this with colleagues: // //